| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. | EVP of R&D | Common Stock | 515 K | $1.64 M | $3.17 | Jan 25, 2024 | Direct |
| Allogene Therapeutics, Inc. | EVP of R&D | Stock Option (Right to buy) | 495 K | Jan 25, 2024 | Direct | ||
| Instil Bio, Inc. | Chief Medical Officer | Employee Stock Option (right to buy) | 245 K | Mar 4, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | Jan 25, 2024 | 2 | $0 | 4 | Jan 31, 2024 | EVP of R&D |
| ALLO | Allogene Therapeutics, Inc. | Jan 22, 2024 | 1 | -$78.4 K | 4 | Jan 24, 2024 | EVP of R&D |
| ALLO | Allogene Therapeutics, Inc. | Mar 22, 2023 | 1 | $0 | 4 | Mar 24, 2023 | EVP of R&D |
| ALLO | Allogene Therapeutics, Inc. | Jan 20, 2023 | 2 | $0 | 4 | Jan 24, 2023 | EVP of R&D |
| ALLO | Allogene Therapeutics, Inc. | Jan 3, 2023 | 0 | $0 | 3 | Jan 9, 2023 | EVP of R&D |
| TIL | Instil Bio, Inc. | Mar 4, 2022 | 1 | $2.11 M | 4 | Mar 7, 2022 | Chief Medical Officer |
| TIL | Instil Bio, Inc. | Oct 7, 2021 | 1 | $0 | 4 | Oct 8, 2021 | Chief Medical Officer |
| TIL | Instil Bio, Inc. | Sep 10, 2021 | 1 | $0 | 4 | Sep 13, 2021 | Chief Medical Officer |
| TIL | Instil Bio, Inc. | May 11, 2021 | 1 | $0 | 4 | May 13, 2021 | Chief Medical Officer |